|
|
EN
  • 业务咨询

    中国:

    Email: marketing@medicilon.com.cn

    业务咨询专线:400-780-8018

    (仅限服务咨询,其他事宜请拨打川沙总部电话)

    川沙总部电话: +86 (21) 5859-1500

    海外:

    +1(626)986-9880(U.S. - West Coast)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在线留言×
点击切换
Customer Center
客户中心
Jun 28,2023
开发并验证新的LC-MS/MS方法,用于定量人血浆中达拉非尼及其主要代谢物羟基达拉非尼 (OHD)。OHD(纯度>99%)通过永乐高合成
OHD (purity >99 %) was synthesized by Medicilon. Medicilon synthetic chemistry team is capable of the independent design of synthesis pathways and complex compound treatments, key to helping accelerate drug discovery.
查看更多
开发并验证新的LC-MS/MS方法,用于定量人血浆中达拉非尼及其主要代谢物羟基达拉非尼 (OHD)。OHD(纯度>99%)通过永乐高合成
Jun 28,2023
放射疗法用作肺癌的主要治疗方法,在次研究中建立抗电离辐射肺癌细胞系的放射治疗通过永乐高进行
Radiation therapy is used as the primary treatment for lung cancer. In this study, radiation therapy for establish ionizing radiation-resistant lung cancer cell lines (A549-IR/H1299-IR) was supported by Medicilon.
查看更多
放射疗法用作肺癌的主要治疗方法,在次研究中建立抗电离辐射肺癌细胞系的放射治疗通过永乐高进行
Jun 28,2023
CAR-T疗法主要针对白血病与恶性淋巴瘤,此研究中构建沉默PD-1的shRNA载体质粒,测序后质粒的鉴定通过永乐高进行
Chimeric antigen receptor T cells (CAR-T) immunotherapy has shown promising clinical results in the treatment of leukemia and lymphoma, but the effectiveness is limited for solid tumors. The shRNA vector plasmid that silences PD-1 and preparation of CAR is constructed. The plasmids sequenced were fully identified by Medicilon.
查看更多
CAR-T疗法主要针对白血病与恶性淋巴瘤,此研究中构建沉默PD-1的shRNA载体质粒,测序后质粒的鉴定通过永乐高进行
Jun 28,2023
索拉非尼的无定形固体分散体用于开发改良型口服生物利用度高的速释片剂,PK研究通过永乐高进行
The SOR ASD tablets exhibited approximately 50% higher relative bioavailability in dogs than the marketed SOR tablet product, Nexavar®. The pharmacokinetic (PK) study of SOR ASD tablets and Nexavar® tablets was performed by Medicilon.
查看更多
索拉非尼的无定形固体分散体用于开发改良型口服生物利用度高的速释片剂,PK研究通过永乐高进行
Jun 28,2023
TAK-931是一种高度特异性的CDC7抑制剂,具有抗肿瘤功效,体内药效研究通过永乐高进行
In vivo efficacy studies in J558 allograft models in combination with anti-mPD-1, anti-mPD-L1, and anti-mCTLA-4 antibodies were performed at Medicilon.
查看更多
TAK-931是一种高度特异性的CDC7抑制剂,具有抗肿瘤功效,体内药效研究通过永乐高进行
Jun 28,2023
GS-5801是一种有效的KDM5抑制剂,具有抗HBV活性,GS-5801通过永乐高合成
GS-5801, a potent inhibitor of KDM5, has antiviral activity against HBV in a primary human hepatocytes infection model, with the cellular permeability, oral bioavailability. GS-5801 was synthesized by Medicilon.
查看更多
GS-5801是一种有效的KDM5抑制剂,具有抗HBV活性,GS-5801通过永乐高合成
Jun 28,2023
QF-036是一种高效的HIV-1抑制剂,具有良好的和药代动力学特性,PK研究通过永乐高进行
The favourable viral inhibitory activity and pharmacokinetic properties provide critical support for QF-036 as a promising anti-HIV therapeutic candidate. The pharmacokinetic studies were performed by Medicilon.
查看更多
QF-036是一种高效的HIV-1抑制剂,具有良好的和药代动力学特性,PK研究通过永乐高进行
Jun 28,2023
设计合成一种新型选择性的口服有效苏氨酸酪氨酸激酶 (TTK) 抑制剂,PK研究均通过永乐高进行
TTK inhibition is an attractive wide-spectrum strategy for cancer therapy. Researchers designed and synthesized a series of pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable TTK inhibitors. All the pharmacokinetic studies were carried out by Medicilon.
查看更多
设计合成一种新型选择性的口服有效苏氨酸酪氨酸激酶 (TTK) 抑制剂,PK研究均通过永乐高进行
Jun 28,2023
TR-107是人类线粒体蛋白酶ClpP的有效激活剂,PK分析通过永乐高进行
The pharmacokinetic properties of TR‐107 were compared with other known ClpP activators including ONC201 and ONC212. TR‐107 displayed excellent exposure and serum t1/2 after oral administration. Pharmacokinetic analysis were evaluated for pharmacokinetic properties in ICR mice by Medicilon.
查看更多
TR-107是人类线粒体蛋白酶ClpP的有效激活剂,PK分析通过永乐高进行
Jun 28,2023
SKLB-197是一种有效且高度选择性的ATR抑制剂,PK研究通过永乐高进行
SKLB-197, exhibits good pharmacokinetic properties, could be a promising lead compound for drug discovery targeting ATR. The pharmacokinetic (PK) studies were performed by Medicilon.
查看更多
SKLB-197是一种有效且高度选择性的ATR抑制剂,PK研究通过永乐高进行
XML 地图